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Serum/plasma collection and Total RNA extraction
Serum and plasma were processed using standard methodologies and Total RNA was extracted using the Plasma/Serum Circulating RNA Purification Kit (#30000; Norgen Biotek, Ontario, Canada) according to manufacturer's instructions.
microRNA microarray profiling and data analysis 5 µg of Total RNA was shipped to LC Sciences (Houston, USA) for miRNA profiling using a custom array platform (µParaflo® technology) containing 1898 miRNAs (miRBase V18) (Griffiths-Jones et al., 2006) . All QC, labeling (Cy-3), hybridization, scanning, signal background subtraction and global normalization (LOWESS) were performed by LC Sciences as per technical note: (www.lcsciences.com/documents/applicationnotes/Tech-Bull-MicroRNA-Microarray-Data-Analysis.pdf).
Advanced data analyses were performed in Genespring GX12.5 (Agilent Technologies, Santa Clara, USA) using the LOWESS normalized signal intensity values. All values <30 were considered 'background expression' (personal communication with LC Sciences) and changed to 0.01 prior to log2 transformation. So as to identify 'melanocyte-specific' miRNAs that were potentially more relevant to melanoma, samples were classified as either 'melanoma' or 'other cancers' (melanocytes, melanoblasts, nevocyte, and serum derived samples were excluded from these categories). To identify differentially expressed miRNAs, a Mann-Whitney U-test (unpaired) was applied to a 'volcano-plot' analysis with thresholds set at p<0.05 and ≥2 fold. The gene list derived from these analyses was then applied to all samples in an unsupervised manner using hierarchical clustering (Euclidean similarity with average linkage).
miScript quantitative RT-PCR validation
Briefly, all samples included on the microarray along with an extended cohort of melanoma cell lines (as described in (Boyle et al., 2011) ) were reverse transcribed using the miScript II RT Kit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions. Real-time PCR was subsequently performed with a miScript SYBR Green PCR Kit (QIAGEN, Hilden, Germany); with the miRNA primer assays (QIAGEN, Hilden, Germany) hsa-miR-211-5p (#MS00003808), hsa-miR-514-3p (#MS00031948), and RNU-6 (#MS00033740), using the 7900HT Fast Real Time PCR System (Life Technologies, Foster City, CA, USA). Data were analyzed in Microsoft Excel using the ΔCT method compared to RNU6 which was assessed in every sample.
MITF inducible melanoma cell lines and lineage-specific miRNA Taqman Assays
RNA from the MITF inducible cells was used as templates for Taqman miRNA-specific cDNA synthesis as per manufacturer's instructions (Life Technologies, Foster City, USA).
Taqman miRNA assays were performed using miRNA-specific primers for miR-211-5p (000514), miR-514a-3p (001147), miR-204-5p (000508), miR-506-5p (001050), miR-508-3p (001052), miR-509-3p (002236), and miR-509-5p (002235) (along with RNU6 (001973) as an endogenous control) using the 7900HT Fast Real Time PCR System (Applied Biosystems, Foster City, USA) as per manufacturer's instructions. Data were analyzed in Microsoft Excel using the ΔCT method compared to RNU6 which was assessed in every sample. The ΔΔCT was then applied with the induced cell line (MITF and LacZ inducible (control)) and the Negative non-induced cell lines (MITF and LacZ non-induced (control) ). An 'array expression-like value' was produced by using ΔΔCT 2 .
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Biotin pull-downs and microarray hybridizations and data analysis
Synthetic biotinylated microRNA-duplexes were designed for miR-514a (Sequence 1: /5Phos/rUrArCrUrCrUrGrGrArGrArGrUrGrArCrArArUrCrArCrG Sequence 2:
/5Phos/rArUrUrGrArCrArCrUrUrCrUrGrUrGrArGrUrArGrA/3Bio/) along with a scrambled control (Sequence 1:
/5Phos/rUrArUrCrCrCrCrUrUrUrGrCrCrUrGrCrUrUrUrUrCrC/3Bio/ Sequence 2:
/5Phos/rUrArArGrCrUrArGrArCrCrGrGrArGrGrArGrGrGrC) according to specifications detailed in the methodology devised by Cloonan and colleagues (Martin et al., 2014; Wani and Cloonan, 2014) and purchased from Integrated DNA Technologies (Coralville, USA). A step-by-step methodology (Wani and Cloonan, 2014) 
Biotin pull-downs and microarray step-by-step methods
Biotin pull-downs and microarray hybridizations were modified to work with existing transfection conditions for melanoma cell lines. The protocol follows a step-by-step guide which was originally published by the Cloonan lab (Martin et al., 2014; Wani and Cloonan, 2014) .
MATERIALS & REAGENTS
• • Illumina HumanHT-12 v4 Expression BeadChip.
• Dry Ice
EQUIPMENT
• Cell scrapers
• 6-well tissue culture plates (P6)
• Centrifuge capable of spinning 50mL falcon tubes at 1000g
• 50mL Falcons
• Rotating mixer
• DynaMag™-2 magnet; magnetic separator (Life technologies cat. no. 123-21D)
• Bench top Microcentrifuges; one set at 4 o C and one at room temperature, both should be capable of doing at least 10,000g
• Eppendorf LoBind® tubes; 1.5mL
• Nanodrop 1000 spectrophotometer (Thermo Scientific)
• Illumina Bead Array Reader.
• Filter tips (10ul, 20ul, 200μl and 1000μl)
REAGENT SET UP
• Biotin tagged miRNA duplexes: Resuspend lyophilized miRNA duplexes to a final concentration of 200uM. Make working dilution at 50uM.
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▲ CRITICAL Repeat freeze thaw cycles should be avoided.
• Bead Wash Buffer (Once prepared is stable at room temperature for several months):
5mM Tris-Cl pH 7.5 0.5mM EDTA 1M NaCl.
• Solution A (Once prepared is stable at room temperature for several months):
0.1M NaOH 0.05M NaCl in RNase/DNase free H2O.
• Solution B (Once prepared is stable at room temperature for several months):
0.1M NaCl in RNase/DNase free H2O.
• Bead Blocking Solution: Prepare RNase/DNase free water containing 1ug/µL BSA 1ug/µL Yeast tRNA.
▲ CRITICAL This solution must be made fresh on the day of use.
• 
PROCEDURE
Step 1-6: Transfecting the Biotin tagged miRNA duplexes into cells. (Day 1)
• TIMING 24.5 h, 30 mins hands-on 1.
For each miRNA to be tested, seed 5x10 5 cells in 2.5mL media + 10% FCS, no Pen/strep per P6 (at least 8-9 P6 per point tested).
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Optional: Set up 1x P6 dish with 5x10 5 cells as a mock transfection control if desired.
2. Prepare the transfection mix according to the classical Lipofectamine protocol (Mix1 = 1.8ul of miRNA duplex 50uM + 250ul Optimem, Mix2 = 4ul Lipofectamine + 250ul Optimem).
3. Incubate each mix separately for 5min at room temperature.
4. Mix 1 + 2 and Incubate at room temperature for 20min to allow the transfection complexes to form.
5. Add 500ul of the transfection complexes to each of the P6. Swirl the plate gently to ensure that the complexes are distributed uniformly across the plate.
6. Incubate the cells with the transfection complexes at 37ºC and 5% CO2 for 24 h.
Step 7-20: Bead washing and blocking. Bead preparation can be started on the day of transfection (day 1) on a rotating mixer at 4º overnight, or can be done on the day of cell harvesting (day 2) for 2 h at room temperature.
Steps 21-36 Harvesting and lysing transfected cells (Day 2)
• TIMING 1 h , 30 mins hands-on 21. Prepare cell Lysis Buffer and keep buffer on ice till required.
▲ CRITICAL this buffer must be made fresh on the day of use.
22. Retrieve transfection plates from step 6 of the protocol. Aspirate and discard media. 27. Centrifuge the tube at 10 000rpm for 5 minutes at room temperature.
28. Aspirate and discard supernatant.
29. Add 150µl cell lysis buffer to each pellet and gently pipette to resuspend cells.
Put cells in lysis buffer at -80 o C for 20 mins.
31. Allow the cells to thaw out at room temperature.
▲ CRITICAL this freeze thaw step allows for better lysis of cells.
32. Centrifuge tube at 13,000rpm in a bench top centrifuge set at 4ºC for 5 minutes.
33. Transfer the cleared cell lysate to a clean 1.5mL LoBind tube, leaving behind the soft pellet. The final volume of cleared lysate should be ~140µl-150ul.
Transfer 20µL of this cleared lysate to a clean 1.5mL LoBind tube and keep on ice.
This lysate will serve as the control lysate RNA which can be extracted with the miRNeasy mini kit (elution in 30µl).
Note: If processing a mock transfected control, carry out steps 22-33 of protocol on the mock transfection plate and keep mock control lysate on ice for later use.
35. Add NaCl to the cleared lysate to give a final concentration of 1M. For example, add 32.5µL of 5M NaCl to 130µL of lysate, giving a final concentration of 1M NaCl in 162.5ul.
36. Place the tube containing cleared lysate and NaCl on ice.
Steps 37-44 Bead Preparation
• TIMING 15 mins, 15 mins hands-on 37. Prepare wash Buffer and keep buffer on ice till required.
▲ CRITICAL This buffer must be made fresh on the day of use. 50. Aspirate supernatant using pipette and discard. Remove the tube from the DynaMag™-2 magnets.
51. Repeat steps 48 -50 three times.
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▲ CRITICAL These washes are essential and are important for the removal of nonspecifically bound products from the beads.
52. Once the washes are complete, resuspend the beads in 30µL of RNase/DNase free H2O, store on ice and proceed immediately to the next step.
▲ CRITICAL The target mRNAs are captured on these beads. Do not discard.
Steps 53-59 Target ■ PAUSE POINT Samples can now be stored at -80ºC. Alternatively, continue with quantification of RNA.
Step 60 Target mRNA and control RNA Quantification
• TIMING 45mins, 20 mins hands-on 60. The target mRNA and the control lysate RNA can now be quantified on the Nanodrop 1000 spectrophotometer and on an Agilent 2100 Bioanalyser using the Agilent RNA 6000 Pico kit using manufacturer's protocol.
■ PAUSE POINT Samples can now be stored at -80ºC or continue on with RNA amplification.
Step 61-62 Target mRNA Labeling and Amplification
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• TIMING 23 h, 2 h hands-on 61. Amplify and label 160-500ng of captured target mRNA using Illumina® TotalPrep RNA Amplification kit according to manufacturer's instructions. Also amplify and label 160-500 ng of control RNA.
▲ CRITICAL Carry out the 16 hour incubation for the IVT step.
62. Quantify the amplified RNAs on the Nanodrop 1000 spectrophotometer.
Step 63 64. Scan the arrays using an Illumina BeadArray Reader.
65. Extract the expression measurements using the GenomeStudio software.
Site-directed mutagenesis and dual-luciferase reporter assays
Putative binding sites were identified using the miRanda target prediction software (version August 2010) (Enright et al., 2003) . Melanoma cell lines were selected based upon transfection ability along with having detectable (by Western blot) endogenous NF1 protein levels (data not shown). NF1 mRNA expression was determined (relative to RNU6) using a QuantiTect Primer Assay (#QT00065016; QIAGEN) as described previously. Cell viability assays were performed and determined using a modified sulforhodamine B (SRB; Sigma, St Louis, USA) assay (Vichai and Kirtikara, 2006) . Briefly, siRNAs, miRNA mimic, Negative control or LNA's were reverse-transfected with melanoma cell lines and seeded into a 96-well plate then incubated at 37ºC with 5% CO2 for 24hr. A serial 10-fold dilution series (100 nM-0.01 nM) of PLX4032 (Selleckchem, Houston, USA) in DMSO was added across each plate.
Plates were fixed on day 6 with methylated spirits prior to performing the SRB assay and read at 564 nm using a plate reader (Molecular Devices, Sunnyvale, USA).
Western blot and mRNA analysis
Cells were lysed in ice-cold lysis buffer containing 20 mM HEPES, pH 7.8, 0.42 M NaCl, 0.5% NP40, 25% glycerol, 0.2 mM EDTA, 1.5 mM MgCl2, 0.1 mM PMSF and protease and phosphatase inhibitors. Samples (60 μg total protein) were resolved on 4-15% Mini-PROTEAN TGX gels (Bio-Rad, Hercules, USA) and transferred to PVDF membranes using NF1 mRNA expression analysis RNA was reverse transcribed using the miScript II RT Kit (QIAGEN, Hilden, Germany) using the 'HiFlex' Buffer thus enabling both mRNA and miRNA to be analyzed in the same sample. The primer assays were used as described NF1 (#QT00065016) along with (RNU-6). Real-time PCR was performed and analyzed as previously stated.
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(Benjamini-Hochberg). Normalised expression data of 233 miRNAs genes in all samples present on the microarray. Samples are grouped based upon tissue type. Normalised expression data is conditionally formatted (in Microsoft Excel) to assist in data visualisation.
Supplementary Table 2
All miRNAs genes that were ≥10 fold up and downregulated from those listed in Supplementary Table 1 are summarized here along with their relevance to melanoma.
Supplementary Table 3
Summary of all cell line names and associated tissue type that were used in the discovery (microarray) and validation cohorts (qRT-PCR).
Supplementary Table 4
List of all genes that we upregulated in 2/2 melanoma cell lines following a biotinlabelled miR-514a duplex pulldown of mRNA transcripts.
Supplementary Table 5
List of all possible binding sites of miR-514 in the NF1 transcript (5'UTR, coding, and 3'UTR) using the miRanda prediction algorithm. Binding threshold is set to 100 (default=140).
Supplementary Table 6
Table of P values associated with BRAFi sensitivity for the melanoma cell lines MM96L
and MM253 ( Figure 5A-B) . T-tests were performed with comparisons were made between siNF1 vs miR-514a; siNF1 vs siNF1+miR-514a; siNF1 vs miR-Neg-scr; miR-
